By Fineline Cube 
WuXi Biologics (Cayman) Inc. (HKG: 2269), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced its unaudited interim results for the first half of 2025. The company reported a 16.1% year-on-year (YoY) increase in revenue to RMB 9,953.2 million. Revenue from continuing operations grew by 20.2%. IFRS gross profit rose by 27.0% YoY to RMB 4,252.9 million, with an IFRS gross profit margin of 42.7%.
Growth Drivers
The revenue growth was primarily attributed to:
- The success of the Group’s “Follow and Win the Molecule” strategies, supported by leading technology platforms and strong execution.
- An expanded service range across the biologics value chain, including discovery, pre-IND development, and clinical and commercial manufacturing, with significant growth in platforms such as antibody-drug conjugates (ADCs) and bi- & multi-specific antibodies.
- Increased research services revenue driven by cutting-edge technologies.
- Enhanced utilization of existing and newly expanded capacity, including the ramp-up of the European manufacturing facility.
Project and Backlog Highlights
In the first half of 2025, the Group added 86 integrated projects, bringing the total to 864, with over half originating from U.S. clients. The Group supports 67 late-stage and 24 commercial projects. The total backlog increased to USD 20.34 billion, with the backlog within 3 years reaching USD 4.21 billion.
WuXiHigh 2.0 Platform
During the reporting period, WuXi Biologics launched WuXiHigh 2.0, its next-generation high-throughput formulation platform for high-concentration biologics. This platform enables protein concentrations of up to 230 mg/mL and reduces viscosity by up to 90%, while maintaining stability and injectability.-Fineline Info & Tech